Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk

Journal of Clinical Pharmacology

Volumn 36, Issue 1, 1996, Pages 42-47

  Taddio, Anna ^c   Ito, Shinya ^a,b,d   Koren, Gideon ^a,b,e  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Natl Hlth R and D Program   (Canada)

^e ONTARIO MINISTRY OF HEALTH AND LONG TERM CARE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; FLUOXETINE; NORFLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AFFECTIVE NEUROSIS; ANXIETY NEUROSIS; ARTICLE; BREAST FEEDING; CLINICAL ARTICLE; CLINICAL PROTOCOL; DEPRESSION; DOSE RESPONSE; DRUG MILK LEVEL; FEMALE; HUMAN; INFANT; MALE; PERINATAL DRUG EXPOSURE;

EID: 0030024605     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04150.x     Document Type: Article

References (18)

1. Altamura AC, Moro AR, Percudani M: Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994;26:201-214.
2. Gram LF: Fluoxetine. New Engl J Med 1994;331:1354-1361.
3. Isenberg KE: Excretion of fluoxetine in human breast milk. J Clin Psychiatr 1990;51:169.
4. Burch KJ, Wells BG: Fluoxetine/norfluoxetine concentrations in human milk. Pediatrics 1992;89:676-677.
5. Lester BM, Cucca J, Andreozzi L, Flanagan P, Oh W: Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatr 1993;32:1253-1255.
6. Koren G, MacLeod SM: Monitoring and avoiding drug and chemical teratogenicity. Can Med Assoc J 1986;135:1079-1081.
7. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G: Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol 1993; 168: 1393-1399.
8. Nash JF, Bopp RJ, Carmichael RH, Farid KZ, Lemberger L: Determination of fluoxetine and norfluoxetine in plasma by gas chromatography with electron-capture detection. Clin Chem 1982;28: 2100-2102.
9. Bennett PN, and the WHO Working Group: Drugs and Human Lactation Amsterdam: Elsevier, 1988.
10. Anderson PO: Drug use during breast-feeding. Clin Pharm 1991;10:594-624.
11. Taddio A, Ito S: Drug use during lactation. In, Koren G (ed.): Maternal-Fetal Toxicology: A Clinician's Guide. New York: Marcel Dekker, 1994;133-219.
12. Treluyer J-M, Jacqz-Aigrain E, Alvarez F, Cresteil T: Expression of CYP2D6 in developing human liver. Eur J Biochem 1991;202:583-588.
13. Riddle MA, Scahill L, King RA, Hardin MT, Anderson GM, Ort SI, et al: Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Adolesc Psychiatr 1992;31:1062-1069.
14. Cooper GL: The safety of fluoxetine: an update. Br J Psychiatr 1988;153:77-86.
15. Altamura AC, Montgomery SA, Wernicke JF: The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. Br J Psychiatr 1988;153(Suppl 3):109-112.
16. Jain U, Birmaher B, Garcia M, Al-Shabbout M, Ryan N: Fluoxetine in children and adolescents with mood disorders: a chart review of efficacy and adverse effects. J Child Adolesc Psychopharmacol 1992;2:259-265.
17. Riddle MA, King RA, Hardin MT, Ort SI, Leckman JF: Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol 1991;1:193-198.
18. Cook EH, Rowlett R, Jaselskis C, Leventhal BL: Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatr 1992;31:739-745.